Skip to main content
SpringerLink
Log in

Overcoming barriers to early disease intervention

  • Correspondence
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: Differences in primary prevention, secondary prevention and early disease intervention, depicting target groups, goals and examples for each approach.
Fig. 2: Hypothetical illustrative example of integrated early disease intervention paradigm.

References

  1. Anonymous. Nat. Biotechnol. 37, 197 (2019).

  2. Bluestone, J. A., Herold, K. & Eisenbarth, G. Nature 464, 1293–1300 (2010).

    Article  CAS  Google Scholar 

  3. Diabetes Prevention Trial–Type 1 Diabetes Study Group. N. Engl. J. Med. 346, 1685–1691 (2002).

  4. Egan, M. F. et al. N. Engl. J. Med. 380, 1408–1420 (2019).

    Article  CAS  Google Scholar 

  5. Demongeot, J. et al. Int. J. Mol. Sci. 10, 4437–4473 (2009).

    Article  CAS  Google Scholar 

  6. Foust, K. D. et al. Nat. Biotechnol. 28, 271–274 (2010).

    Article  CAS  Google Scholar 

  7. Groen, E. J. N., Talbot, K. & Gillingwater, T. H. Nat. Rev. Neurol. 14, 214–224 (2018).

    Article  Google Scholar 

  8. Dominguez, E. et al. Hum. Mol. Genet. 20, 681–693 (2011).

    Article  CAS  Google Scholar 

  9. US Food and Drug Administration. https://www.fda.gov/vaccines-blood-biologics/zolgensma (2019).

  10. Hickey, R. D. et al. Cell Transplant. 28, 79–88 (2019).

    Article  Google Scholar 

  11. Herold, K. C. et al. N. Engl. J. Med. 381, 603–613 (2019).

    Article  CAS  Google Scholar 

  12. Korde, N. et al. JAMA Oncol. 1, 746–754 (2015).

    Article  Google Scholar 

  13. Landgren, O. et al. Leukemia 33, 2127–2143 (2019).

    Article  CAS  Google Scholar 

  14. Zhao, A. L. et al. Cancer Manag. Res. 11, 5599–5611 (2019).

    Article  CAS  Google Scholar 

  15. Pentland, A. Social Physics Vol. 1 (Penguin, 2015).

Download references

Acknowledgements

Our perspective has benefited from a global network of colleagues. In particular, it has been challenged, informed and enriched by conversations with many people, including R. Hendricks, D. Blumenthal, B. Wiegand, K. Wildenhaus, J. Hedrick, S. Brady, G. Pigino, J. M. Peyrin, P. Prieto, J. Fleming and A. Zarur.

Author information

Authors and Affiliations

  1. Connection Science, Massachusetts Institute of Technology, Cambridge, MA, USA

    H. Hugo Caicedo & Alex Pentland

  2. Corporate Sustainability and Innovation, Harvard University, Cambridge, MA, USA

    H. Hugo Caicedo

  3. Department of Surgery, Massachusetts General Hospital, Boston, MA, USA

    Daniel A. Hashimoto

  4. Harvard Medical School, Boston, MA, USA

    Daniel A. Hashimoto

  5. Materials Engineering, Universidad del Valle, Cali, Colombia

    Julio C. Caicedo

  6. Technology and Operations Management, Harvard Business School, Boston, MA, USA

    Gary P. Pisano

Authors
  1. H. Hugo Caicedo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel A. Hashimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Julio C. Caicedo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alex Pentland
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Gary P. Pisano
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H. Hugo Caicedo.

Ethics declarations

Competing interests

D.A.H. consults for Johnson & Johnson, Verily Life Sciences, and Worrell. He has received research support from Olympus. A.P. is on the Advisory Boards of Pear Therapeutics. G.P.P. consults for Johnson & Johnson, Takeda, Bristol-Myers Squibb, Eli Lilly and Tolero, and serves on the Board of Directors of Axcella Health and Celixir.

Additional information

Editorial note: This article has been peer reviewed.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Caicedo, H.H., Hashimoto, D.A., Caicedo, J.C. et al. Overcoming barriers to early disease intervention. Nat Biotechnol 38, 669–673 (2020). https://doi.org/10.1038/s41587-020-0550-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41587-020-0550-z

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation